GNTA genenta.com: Enterprise Value to EBITDA Ratio

genenta.com (GNTA) - corporate logo

The price chart on the GURU.Markets platform for Genenta Science S.p.A. (GNTA) shows an EV/EBITDA multiple of 0.00. The management of this European biotech is renowned for its scientific integrity and transparent reporting. Business development relies on the modification of macrophages using viral vectors to combat tumors. However, the absence of commercial drugs makes the valuation of the Italian startup dependent on the results of clinical trials.

Genenta Science - GNTA Enterprise Value to EBITDA Ratio (period 11/23/2025 - 11/04/2026)

genenta.com (GNTA) - metric breakdowns and financial figures

- stock price and consensus target price:
Stock Quotes Genenta Science|GNTA - Average Forecast Price
- company stock capitalization data:
Market Valuation Genenta Science S.p.A.|GNTA - Value Adjusted for Debt and Cash
- business book valuation details:
Book Value per Share Genenta Science|GNTA - Company Net Assets|Market Capitalization to Book Value Ratio genenta.com|GNTA - Company Assets
- debt and solvency information:
Debt to Equity Genenta Science S.p.A.|GNTA - Long-Term Debt to Equity|Short-Term Debt to Equity Genenta Science|GNTA - Company Debts|Debt to Book Value Genenta Science S.p.A.|GNTA - Company Long-Term Loans and Borrowings|Company Short-Term Debts Genenta Science|Quick Ratio genenta.com
- financial results and valuation multiples details:
GNTA - Company Net Income|Expected Profit Genenta Science S.p.A.|GNTA - Price to Earnings Multiple|Forward P/E Multiple Genenta Science|GNTA - Price to Earnings Adjusted for Growth Rate|Enterprise Value to EBITDA Ratio Genenta Science S.p.A.|GNTA - Income before deduction of interest, taxes and amortization|Net earnings per share for the last 12 months Genenta Science|GNTA - Earnings per share for the last four quarters|Quarterly EPS earnings growth genenta.com|GNTA - Earnings per share increase in current year|Earnings growth forecast for next year Genenta Science S.p.A.
Summary company analytics:Genenta (GNTA)
Original product of Genenta Science

This indicator measures the ratio of total enterprise value, including debt, to operating profit, allowing for an assessment of the real value of assets excluding the tax burden. For Genenta Science (GNTA), which invests in a costly staff of unique geneticists, the EV/EBITDA multiple valuation is critically important, as it correlates high operating personnel costs with the company's market capitalization.

Key competitors

Legend Biotech Inc. - Enterprise Value to EBITDA Ratio|Sana Corp (SANA) - Company Value to EBITDA|AUTL: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation ALLO (allogene.com)|RNAC: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Cellectis|CRBU (Caribou Bio) - EV/EBITDA Multiple|Company Value to EBITDA Instil Bio Inc TIL|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Century Therapeutics (IPSC)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization JSPR (jaspertherapeutics.com)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Senti Biosciences SNTI|Adaptimmune Therapeutics plc - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CERO: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation TCRT (Alaunos Therapeutics)|ACHL: EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple cargo-tx.com CRGX|PSTX (Poseida Therapeutics, Inc.) - EV/EBITDA Multiple|Company Value to EBITDA 2seventy bio Inc. TSVT|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Gracell Biotechnologies Ltd (GRCL)